Preliminary Results for the year ending 31 December 2020
Avacta Group PLC (AVCT.L) Final Results
Avacta Group PLC (AVCT.L) Clinical validation of AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test
98.0% clinical sensitivity for samples with PCR Ct values [1] up to 31
Avacta Group PLC (AVCT.L) Directorate Change
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the Dr Mike Owen has stepped down
Avacta Group PLC (AVCT.L) Rapid Antigen Test Detects SARS-CoV-2 Variants
Avacta’s AffiDX® SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus
Avacta Group PLC (AVCT.L) Significant momentum in both Diagnostics and Therapeutics Divisions
AffiDX®, SARS-CoV-2 Lateral Flow Rapid Antigen Test generates excellent initial clinical sensitivity and specificity data MHRA approves Clinical Trial Authorisation of first therapeutic product candidate
Avacta Group PLC (AVCT.L) Re: Press Speculation
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, notes the recent press speculation about UK Government take-up of Avacta’s lateral flow SARS-CoV-2 rapid antigen test.
Avacta Group PLC (AVCT.L) Commercial Partnership with Mologic
Partnership to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries
Avacta Group PLC (AVCT.L) License Agreement with POINT Biopharma Inc.
License to utilise Avacta’s pre|CISIONTM FAP sensitive activation platform for radiopharmaceuticals
Avacta Group PLC (AVCT.L) SARS-CoV-2 Rapid Antigen Test Update
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, is pleased to announce significant progress in the development
TPI provides its latest research note on Avacta Group Plc (AVCT.L).
Avacta released its unaudited interim results for the six-month period ended 30 June 2020 on Monday. They detailed a period of significant advancement for the Group despite the restrictions placed upon it
Avacta Group plc (AVCT.L) Launch of SARS-CoV-2 BAMSTM Research Test
Affimer-based research assay launched alongside performance data published by Bruker
